Current Report Filing (8-k)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT
TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 20, 2017

SECOND SIGHT MEDICAL PRODUCTS, INC.
(Exact Name of Registrant as Specified in Its Charter)

California
(State or Other Jurisdiction of Incorporation)

	333-198073	02-0692322
	(Commission File Number)	(IRS Employer Identification No.)

	12744 San Fernando Road, Suite 400 Sylmar, California 91342
	(Address of Principal Executive Offices)

	(818) 833-5000
	(Registrant's Telephone Number, Including Area Code)


	(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Departure of Chief Financial Officer.

On June 20, 2017, Thomas B. Miller, Chief Financial Officer of Second Sight Medical Products, Inc. (the “Company”), notified the Company that he was submitting his resignation as Chief Financial Officer to pursue other opportunities. Mr. Miller agreed to remain in his current role until the Company announces its second quarter results and files the Quarterly Report on Form 10-Q for the period which ends June 30, 2017. Mr. Miller’s announced departure did not result from a disagreement with the Company on any matter relating to the Company’s operations, policies or practices. The Company has commenced an executive search to identify a suitable replacement for the role.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: June 23, 2017

SECOND SIGHT MEDICAL PRODUCTS, INC.

/s/ Jonathan Will McGuire

By: Jonathan Will McGuire

Title: President and Chief Executive Officer